Legend Bio to Launch CAR-T in Europe for Multiple Myeloma
publication date: May 27, 2022
Legend Biotech, a Nanjing-New Jersey cell therapy company, was approved to launch its CAR-T therapy, Carvykti®, in Europe for patients with multiple myeloma. In a Phase Ib/II pivotal trial that enrolled patients who had received at least three prior treatments regimens, Carvykti® produced an overall response rate of 98% and an 80% complete response rate. In 2017, Legend stunned an ASCO meeting with news that its CAR-T showed a very high 94% complete response rate. Janssen, a J&J company, paid $350 million upfront later that year to partner the drug. More details....
Stock Symbol: (NSDQ: LEGN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.